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Two recent studies, including one reported in this issue of
Cancer Cell, link the signaling pathways responsible for the
hamartomatous syndromes Peutz-Jeghers and tuberous scle-
rosis complex (Corrandeti et al., 2004; Shaw et al., 2004a). Both
PJS and tuberous sclerosis complex are inherited in an autoso-
mal dominant manner, and both are characterized by multiple
hamartomas.
The term hamartoma refers to benign tumors that are com-
posed of multiple cell types native to the tissue from which they
arise. Hamartomas can develop in multiple tissues. In PJS,
these lesions develop primarily in the intestine, where they grow
as polyps. PJS is also characterized by abnormal mucocuta-
neous pigmentation and an increased risk of malignant tumors
in the intestine and elsewhere (Wirtzfeld et al., 2001). In tuber-
ous sclerosis complex, hamartomas primarily develop in the
brain, heart, kidney, and skin.
Peutz-Jeghers results from mutations in the LKB1 tumor
suppressor gene (Hemminki et al., 1998; Jenne et al., 1998).
LKB1 is a serine-threonine kinase, and most of the LKB1 muta-
tions linked to PJS are known or predicted to inactivate its cat-
alytic activity (Boudeau et al., 2003). The best-characterized
substrate of LKB1 is AMPK (Hawley et al., 2003; Woods et al.,
2003; Shaw et al., 2004b). AMPK is a serine-threonine kinase
that functions in a pathway that integrates signals from energy
stores (Carling, 2004). As cellular ATP decreases and AMP lev-
els rise, LKB1 activates AMPK, which in turn phosphorylates
many substrates involved in energy conservation pathways. In
this setting, LKB1 can be viewed as an AMPKK.
Tuberous sclerosis complex results from mutations in either
the TSC1 or TSC2 tumor suppressor gene (Cheadle et al.,
2000). The TSC2 protein (also called tuberin) is a substrate of
AMPK (Inoki et al., 2003). TSC2 binds TSC1 (also called
hamartin) to form a tumor suppressor complex (for simplicity we
will refer to the hamartin/tuberin complex as TSC1/2). TSC1/2
functions in a signal transduction pathway that integrates sig-
nals from a variety of sources with the protein translation appa-
ratus through the regulation of mTOR. Under conditions that are
adverse for proliferation (such as in the absence of nutrients or
certain growth factors), TSC1/2 is activated and inhibits mTOR.
TSC2 functions as a GAP (GTPase activating protein) toward
the small Ras-like GTPase Rheb (Fingar and Blenis, 2004). In
its active, GTP bound form, Rheb activates mTOR, through a
mechanism that is not completely understood. Phosphorylation
of TSC2 by AMPK pursuant to energy starvation leads to
enhanced TSC2 function, as determined by enhanced inhibition
of mTOR (Inoki et al., 2003).
mTOR is a serine-threonine kinase. The best-characterized
substrates of mTOR are S6K1 and 4E-BP1 (Fingar and Blenis,
2004). S6K1 is activated by phosphorylation and, in turn, phos-
phorylates the 40S ribosomal S6 protein. S6 phosphorylation
has been hypothesized to increase the translation of a class of
mRNAs that encode components of the protein translation
machinery and possess a terminal oligopyrimidine (TOP) tract
in their 5′UTRs. Phosphorylation of 4E-BP1 releases the
eukaryotic initiation factor eIF-4E, which then recruits other
components of the eIF-4 complex to the 5′ end of cap-bearing
mRNAs, thus stimulating protein translation.
The most recent findings have now established that LKB1
regulates TSC1/2 through AMPK, thereby linking the LKB1
tumor suppressor gene to the TSC1/2 tumor suppressor path-
way. Activation of LKB1 results in phosphorylation and activa-
tion of AMPK. In turn, AMPK phosphorylates and activates
TSC2, thereby inhibiting mTOR (Corrandeti et al., 2004; Shaw
et al., 2004a). By inhibiting mTOR, AMPK stalls a major energy-
consuming process: the translation of proteins and, in particu-
lar, the translation of proteins comprising the translational
machinery itself.
TSC1/2 function is also regulated by the tumor suppressor
protein, PTEN. Germline PTEN mutations result in a variety of
clinical syndromes. Notably, two of these syndromes, Cowden
syndrome and Bannayan-Riley-Ruvalcaba syndrome (BRRS),
are also characterized by hamartomas (Eng, 2003). PTEN is a
dual specificity phosphatase that catalyzes the conversion of
PIP3 (phosphatidylinositol 3,4,5 triphosphate) to PIP2
(Phosphatidylinositol 4,5 biphosphate) (Cantley, 2002). PIP3 is
an important second messenger whose levels are tightly regu-
lated. In response to growth factor stimulation, intracellular PIP3
levels rise transiently, leading to activation of multiple effectors,
including Akt and PDK1. In the absence of PTEN, increased
levels of PIP3 result in an abnormal activation of these effector
proteins. Akt directly phosphorylates TSC2, which leads to
decreased TSC2 GAP activity (Inoki et al., 2002; Manning et al.,
2002; Potter et al., 2002).
Hence, two different tumor suppressor pathways converge
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to regulate TSC1/2 (Figure 1). Loss of LKB1 results in
decreased activation of AMPK and the downregulation of
TSC1/2 function. Loss of PTEN increases Akt activity, which
also downregulates TSC2 function. This may explain the devel-
opment of hamartomas in Cowden syndrome (and BRRS), PJS,
and tuberous sclerosis complex. How inactivation of TSC1/2
leads to hamartoma development is not known. Hamartomas
arising in tuberous sclerosis complex patients do show evi-
dence of mTOR activation (El-Hashemite et al., 2003b).
Similarly, polyps from LKB1+/− mice also exhibit increased phos-
phorylation of mTOR effectors (Shaw et al., 2004a). These
observations are at least consistent with the notion that
dysregulation of mTOR contributes to the development of
hamartomas.
Precisely how the regulation of mTOR and protein transla-
tion is linked to cell proliferation control is an area of intense
investigation. It is intriguing, however, that genes encoding
translation factors are sometimes amplified in cancers, trans-
form cells in tissue culture, and cooperate with other oncogenes
to cause tumors in mice (Holland et al., 2004). The protein elon-
gation factor, eEF-1α2, is amplified in ovarian tumors and, when
overexpressed, allows NIH 3T3 cells to grow in anchorage-inde-
pendent conditions and enhances focus formation (Anand et al.,
2002). Ectopic expression of the translation initiation factor eIF-
4E allows clonal expansion and anchorage-independant growth
of mammary epithelial cells (Avdulov et al., 2004), and inhibition
of eIF-4E blocks cell proliferation (De Benedetti and Graff,
2004). eIF-4E also cooperates with Myc to promote tumor
development in mice (Ruggero et al., 2004; Wendel et al.,
2004).
One of the pathways regulated by changes in mTOR activi-
ty involves the hypoxia-inducible transcription factor, HIF
(Hudson et al., 2002). HIF is a heterodimeric transcription factor
composed of an α and a β subunit that regulates a gene expres-
sion program that is important for adaptation to hypoxia. HIF is
regulated by oxygen levels through oxygen-dependent hydroxy-
lation of two prolyl residues in the α subunit (Kaelin, 2002).
Hydroxylation of these residues targets HIF-α for polyubiquity-
lation by a multiprotein complex that contains pVHL, which is
encoded by the von Hippel-Lindau tumor suppressor gene
(Kaelin, 2002). Polyubiquitylation, in turn, earmarks HIF for
destruction by the proteasome.The role of HIF in tumorigenesis
has been most clearly established in the context of von Hippel-
Lindau disease, which is caused by inactivating VHL mutations.
The tumors that arise in this setting, including blood vessel
tumors called hemangioblastomas and clear cell renal carcino-
mas, exhibit high levels of HIF. Elimination of HIF in pVHL-
defective renal carcinoma cells using HIF shRNA, or by
reintroducing wild-type pVHL, is sufficient to suppress their abil-
ity to form tumors in nude mice (Kondo et al., 2003; Zimmer et
al., 2004). Moreover, expression of a stabilized form of HIF that
evades pVHL control is sufficient to restore tumorigenesis in
pVHL-deficient tumor cells reconstituted with wild-type pVHL
(Kondo et al., 2002; Maranchie et al., 2002). Hence, HIF clearly
plays a causal role in the development of pVHL-defective
tumors.
HIF is thought to contribute to tumor development through
increased expression of growth factors such as TGFα, PDGFβ,
and VEGF. In addition, HIF also increases the expression of glu-
cose transporters and glucose metabolic enzymes, which might
also influence tumor development and have been linked to the
characteristic metabolic changes observed in tumors referred to
as the “Warburg Effect” (Dang and Semenza, 1999). Regulation
of mTOR by HIF is likely to involve changes in HIF stability as
well as changes in HIF mRNA accumulation (Brugarolas et al.,
2003; Hudson et al., 2002). It is attractive to speculate that reg-
ulation of HIF by mTOR is a means of coupling changes in nutri-
ent availability to changes in glucose uptake and metabolism,
mitogenesis, and tissue angiogenesis. For example, increased
angiogenesis would enhance the delivery of oxygen and nutri-
ents to a tissue undergoing growth and expansion.
In keeping with the above considerations, HIF is regulated
by growth factor availability as well as by changes in oxygen.
Regulation of HIF by growth factors involves TSC1/2, because
TSC2-deficient cells, in contrast to normal cells, fail to downreg-
ulate HIF in response to growth factor deprivation (Brugarolas
et al., 2003). Failure to downregulate HIF in TSC2-deficient cells
has functional consequences as determined by increased
expression of HIF target genes such as VEGF (Brugarolas et
al., 2003; El-Hashemite et al., 2003a; Liu et al., 2003). Notably,
expression of a disease-associated TSC2 mutant (in contrast to
wild-type TSC2) in TSC2-deficient cells fails to normalize HIF
(and VEGF), suggesting that the regulation of HIF might be
important for TSC2 tumor suppression function (Brugarolas et
al., 2003; El-Hashemite et al., 2003a). The regulation of HIF by
TSC1/2 involves mTOR, because HIF levels in TSC2-deficient
cells are normalized by treatment with the mTOR inhibitor
rapamycin (Brugarolas et al., 2003).
PTEN is also involved in the regulation of HIF (Zundel et al.,
2000), and activation of the PI3 kinase pathway results in the
upregulation of HIF and its target genes (Jiang et al., 2001;
Mazure et al., 1997; Zhong et al., 2000). Expression of a consti-
tutively active form of Akt in a transgenic mouse model in the
prostate increases the expression of HIF and its targets
(Majumder et al., 2004). As was true for TSC2-deficient cells,
treatment of these mice with a rapamycin analog normalizes the
levels of HIF and HIF target genes (Majumder et al., 2004).
Increased HIF and VEGF levels may be a common, and
perhaps unifying, feature of the familial hamartoma syndromes
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Figure 1. Signaling mechanisms by LKB1, PTEN, and TSC1/2 tumor
suppressors
Dashed lines indicate functional interactions with incompletely understood
mechanisms.
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and VHL disease. Rodent cells lacking Tsc1 or Tsc2 overpro-
duce VEGF (Brugarolas et al., 2003; El-Hashemite et al.,
2003a; Liu et al., 2003), and VEGF protein levels are increased
in angiofibromas from tuberous sclerosis complex patients
(Nguyen-Vu et al., 2001). Interestingly, VEGF protein levels are
also elevated in LKB1-deficient cells (Ylikorkala et al., 2001).
However, while in TSC2-deficient cells VEGF mRNA levels are
also elevated, it is unclear whether VEGF mRNA levels are ele-
vated in LKB1-deficient cells. In one study, VEGF mRNA levels
were found to be elevated in Lkb1−/− mouse embryos by in situ
hybridization (Ylikorkala et al., 2001). In another study, however,
VEGF mRNA levels in Lkb1−/− mouse embryo fibroblasts
(MEFs) were unchanged compared to wild-type MEFs by
Northern blot (Bardeesy et al., 2002).
The regulation of VEGF by TSC1/2 might involve several
pathways (Figure 1). Rapamycin normalizes HIF levels in TSC2-
deficient cells but fails to completely normalize VEGF, suggest-
ing that VEGF is regulated through both a rapamycin-sensitive
and a rapamycin-insensitive (presumably mTOR-independent)
pathway (Figure 1) (Brugarolas et al., 2003). Corrandeti and
coworkers likewise found that rapamycin partially downregulat-
ed VEGF in LKB1-defective cells, although the effects were not
normalized for the effects of rapamycin on global translation.
With respect to mTOR, there is evidence that mTOR can signal
to VEGF in both HIF-dependent and independent manners
(Mamane et al., 2004).
While there are overlapping features among Cowden syn-
drome (and BRRS), Peutz-Jeghers syndrome, and tuberous
sclerosis complex, these diseases differ in many ways, includ-
ing the cells and organs that primarily give rise to tumors.These
differences might be explained, at least partly, if the pathway
depicted in Figure 1 is in fact far more complex, with each tumor
suppressor protein performing some nonredundant function(s)
that is not linearly connected to those performed by the others.
Indeed, it has already been shown that LKB1 has other sub-
strates besides AMPK (Lizcano et al., 2004). AMPK phosphory-
lates other proteins besides TSC2 (Carling, 2004), and PIP3
levels, which increase upon PTEN inactivation, regulate many
pathways besides the TSC pathway (Cantley, 2002). It is also
unclear whether LKB1 is the only AMPKK. In summary, the rel-
atively linear pathway depicted in Figure 1 is almost certainly
part of a more complex network, with each tumor suppressor
protein serving as a critical nodal point with multiple branches.
Some of these branch points might involve tissue-specific func-
tions that would link these various tumor suppressor proteins to
specific tumor types.
An immediate question stemming from these findings is
whether rapamycin-like drugs will alter the natural history of the
familial hamartoma syndromes. Encouraging in this regard is
the fact that rapamycin can downregulate HIF and VEGF in a
variety of settings. Rapamycin has been used as an immuno-
suppressant for years but recently has attracted interest as a
potential anticancer agent due to its antiproliferative properties
in vitro and the growing appreciation that many cancer-causing
mutations (including those described here) directly or indirectly
lead to increased mTOR activity (Sawyers, 2003). Interestingly,
PTEN−/− cells are more sensitive than their wild-type counter-
parts to the antiproliferative effects of rapamycin, suggesting
that cells might become “addicted” to high levels of mTOR activ-
ity under certain circumstances (Weinstein, 2002; Sawyers,
2003). Moreover, treatment with rapamycin has little effect on
HIF levels in wild-type MEFs and wild-type mouse prostates (in
contrast to their Tsc2-deficient and transgenic Akt counterparts,
respectively) (Brugarolas et al., 2003; Majumder et al., 2004).
These observations suggest that rapamycin use might be asso-
ciated with a therapeutic window despite the central role of
mTOR in cellular homeostasis.
Along similar lines, a number of agents that inhibit VEGF or
its receptors are currently being tested in man and might theo-
retically prove useful, alone or in combination with rapamycin,
for the treatment of the hamartoma syndromes. Testing these
concepts in clinical trials would be congruent with recent reports
that have firmly established the importance of using cancer
genetics, and knowledge of cancer-relevant molecular path-
ways, to guide cancer therapy (Kaelin, 2004).
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